Literature DB >> 26778815

[Pulmonary sarcomatoid carcinoma].

Martine Antoine1, Thibault Vieira2, Vincent Fallet2, Cécile Hamard3, Michael Duruisseaux3, Jacques Cadranel2, Marie Wislez2.   

Abstract

Pulmonary sarcomatoid carcinomas are a rare group of tumors accounting for about one percent of non-small cell lung carcinoma (NSCLC). In 2015, the World Health Organization classification united under this name all the carcinomas with sarcomatous-like component with spindle cell or giant cell appearance, or associated with a sarcomatous component sometimes heterologous. There are five subtypes: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma and pulmonary blastoma. Clinical characteristics are not specific from the other subtypes of NSCLC. Epithelial to mesenchymal transition pathway may play a key role. Patients, usually tobacco smokers, are frequently symptomatic. Tumors are voluminous more often peripherical than central, with strong fixation on FDG TEP CT. Distant metastases are frequent with atypical visceral locations. These tumors have poorer prognosis than the other NSCLC subtypes because of great aggressivity, and frequent chemoresistance. Here we present pathological description and a review of literature with molecular features in order to better describe these tumors and perhaps introduce new therapeutics.
Copyright © 2016. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Biologie moléculaire/Carcinome bronchique non à petite cellule; Carcinome bronchique non à petite cellule; Carcinomes sarcomatoïdes; Epithelial to mesenchymal transition; Molecular biology/non-small cell carcinoma; Non-small cell carcinoma; Sarcomatoid carcinoma; Therapy/non-small cell carcinoma; Traitement/Carcinome bronchique non à petite cellule; Transition épithélio-mésenchymateuse

Mesh:

Substances:

Year:  2016        PMID: 26778815     DOI: 10.1016/j.annpat.2015.11.007

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  7 in total

1.  Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma.

Authors:  Jiachun Sun; Zhiyi Jiang; Tanyou Shan; Ruina Yang; Dejiu Kong; Junshuai Rui; Xinyang Li; Guoqiang Kong; Baoping Chang
Journal:  Front Oncol       Date:  2022-05-03       Impact factor: 5.738

2.  Omega-6 Polyunsaturated Fatty Acids Enhance Tumor Aggressiveness in Experimental Lung Cancer Model: Important Role of Oxylipins.

Authors:  Mayra Montecillo-Aguado; Belen Tirado-Rodriguez; Gabriela Antonio-Andres; Mario Morales-Martinez; Zhen Tong; Jun Yang; Bruce D Hammock; Rogelio Hernandez-Pando; Sara Huerta-Yepez
Journal:  Int J Mol Sci       Date:  2022-05-31       Impact factor: 6.208

3.  Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report.

Authors:  Emanuela Cimpeanu; Jibran Ahmed; Wahib Zafar; Adreana DeMarinis; Svetoslav S Bardarov; Shamim Salman; Dennis Bloomfield
Journal:  World J Clin Cases       Date:  2020-01-06       Impact factor: 1.337

4.  Clinical, pathological and treatment factors associated with the survival of patients with pulmonary sarcomatoid carcinoma.

Authors:  Xiaohong Liang; Yinan Cheng; Zijiang Yuan; Zhengping Yan; Quqing Li; Yuan Huang; Gaohua Feng
Journal:  Oncol Lett       Date:  2020-03-23       Impact factor: 2.967

5.  Case Report: First Case of Consolidation Immunotherapy After Definitive Chemoradiotherapy in Mediastinal Lymph Node Metastatic Sarcomatoid Carcinoma.

Authors:  Yu Wang; Lin Yang; Jianyang Wang; Lin Gui; Wei Li; Zhiqiang Liu; Xiangyu Ma; Yin Yang; Luhua Wang; Nan Bi
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

6.  Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report.

Authors:  Hideyuki Niwa; Sakiko Otani; Norihiro Nakada; Jiichiro Sasaki; Hideo Saka; Noriyuki Masuda
Journal:  Respir Med Case Rep       Date:  2018-02-02

Review 7.  Updated Prognostic Factors in Localized NSCLC.

Authors:  Simon Garinet; Pascal Wang; Audrey Mansuet-Lupo; Ludovic Fournel; Marie Wislez; Hélène Blons
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.